AIM Rule 26

The following information is being disclosed for the purposes of Rule 26 of the AIM Rules for Companies.

About ImmuPharma

Please click below for a description of the business.

About Us
Portfolio

Country of Incorporation and Main Country of Operation

Country of Incorporation: England and Wales
Company Registration Number: 3929567
Main Country of Operation: France

Registered Office

One Bartholomew Close, London, EC1A 7BL UK

Corporate Governance
Please click below for details of ImmuPharma’s Corporate Governance procedure
Corporate Governance

Company Reports

Annual Report and Accounts 2020

Click on the link above for the Immupharma plc Annual Report 2020 .

Please note the file may take a few minutes to open.

It is recommended you save the report on your hard drive; download and then right click on the photo and choose “Save As” and then save it on your computer before you open it.

Annual Report and Accounts 2019
Annual Report December 2018
Annual Report December 2017
Annual Report December 2016
Annual Report December 2015

Annual Report December 2014
Annual Report December 2013
Annual Report December 2012
Annual Report December 2011
Annual Report December 2010
Annual Report December 2009
Annual Report December 2008
Annual Report December 2007
Annual Report March 2006

Latest Interim Report

Interim Results June 2020

Notifications

NOTICE OF ANNUAL GENERAL MEETING ON  28 JUNE 2021 @ 10.30 AM (BST)

ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM), the specialist drug discovery and development company, confirms that the Annual Report and Accounts for the year ended 31 December 2020, and the Notice of Annual General Meeting has been posted to shareholders.

These documents are available, in electronic form, for download on the Company’s website www.immupharma.co.uk

ImmuPharma’s Annual General Meeting (AGM) will be held on Monday, 28 June 2021 @ 10.30am (BST) at: 525 Wilton Road, Victoria, London SW1V 1LW

COVID-19 Guidance

Government guidance in the UK relating to COVID-19 continues to place restrictions on public gatherings, so shareholders will not be permitted to attend the AGM in person. The AGM will therefore be held with the minimum attendance necessary to form a quorum (which will be facilitated by the Company).

In light of those measures, we strongly encourage you to consider ensuring your vote is counted by submission of the proxy by post. Please complete the paper proxy that accompanies this notice and return it to the Company’s Registrar, Computershare Investor Services plc, The Pavilions, Bridgwater Road, Bristol, BS99 6ZY. All proxy forms must be received by no later than 48 hours prior to the AGM, being 10:30am on Thursday 24 June 2021.

Investor Meet Company | Virtual Participation

In order to ensure that shareholders are able to follow the proceedings of the AGM, the Company will provide a live broadcast of the AGM through the Investor Meet Company (“IMC”) platform. However, shareholders will not be able to vote online during the AGM and are therefore urged to submit their votes via proxy as early as possible. Shareholders are also invited to submit written questions for the Board to consider. Questions can be pre-submitted in advance of the AGM via the IMC platform up to 09:00am on 25 June 2021, being the working day before the AGM, or via the IMC platform at any time during the AGM itself. The Board will respond to key questions during the meeting and will provide such answers via the IMC platform thereafter. Shareholders who wish to attend the AGM online should register for the event in advance via the following link:

https://www.investormeetcompany.com/immupharma-plc/register-investor

Please contact Lisa Baderoon at lisa.baderoon@immupharma.com if you have any questions regarding the AGM.

Advisers

Nominated Adviser ‘NOMAD”
SPARK Advisory Partners Limited
5 St John’s Ln, Clerkenwell, London EC1M 4BH
Tel +44 20 3368 3550

Joint Broker
Stanford Capital Partners Limited
15-17 Eldon Street, London EC2M 7LD
Tel +44 203 815 8880

Joint Broker
Si Capital Limited
43 Brook Street, Mayfair, London W1K 4HJ
Tel +44 203 841 6178

Public and Investor Relations
Lisa Baderoon
lisa.baderoon@immupharma.com
investors@immupharma.com

Solicitors
Bircham Dyson Bell, One Bartholomew Close, London EC1A 7BL U.K.

Auditors
Nexia Smith & Williamson Chartered Accountants
25 Moorgate London EC2R 6AY, UK

Principal Bankers
Royal Bank of Scotland plc
62/63 Threadneedle Street, London EC2R 8LA, UK

Registrars
Computershare Investor Services PLC, PO Box 82, The Pavilions, Bridgewater Road, Bristol, BS99 7NH, UK

Current Constitutional Documents

Please click below for details of current constitutional documents.

Constitutional documents

For all notifications, please check the Regulatory News section.

Details of Any Other Exchanges or Trading Platforms

ImmuPharma has a dual listing with Euronext Growth Brussels (Euronext) and shares can be traded under the ticker ‘ALIMM’ from 19 December 2019 when admission to Euronext takes effect. In addition to AIM, this dual listing on Euronext allows ImmuPharma to join the number one European stock exchange for Life Sciences and the world’s second biggest for biotech companies after the United States.

The Company’s shares are also traded in Germany. ‘Tradegate’ which is an open market listing on the Berlin Exchange and the ‘third segment’ of the Stuttgart Stock Exchange.

Number of Securities In Issue and Significant Shareholders

ImmuPharma has 250,221,297 ordinary shares of 10p each in issue, each of which entitles the holder to cast one vote in general meetings. The Company does not hold any Ordinary Shares in treasury. As at 17 August 2021, major shareholders that hold more than 3% of the share capital of ImmuPharma, confirmed through a TR1, are detailed below:

  Number of Ordinary 10p shares % of issued share capital
Luca & Associates AG

Lanstead Capital Investors LP

22,000,000

14,291,472

8.88%

5.71%

*The breakdown of the Director’s holding is:
Tim McCarthy
(Chairman & Chief Executive Officer)
288,462 0.12%
Dr Tim Franklin
(Chief Operating Officer)
125,000 0.05%
Dr Sanjeev Pandya
(Senior Non-Executive Director)
125,000 0.05%
Lisa Baderoon
(Non-Executive Director and Head of Investor Relations)
183,963 0.07%

As far as the Company is aware, the percentage of ImmuPharma’s issued share capital that is not in public hands is under 1%.  This percentage comprises the holdings of Directors only.

ImmuPharma is subject to the UK City Code on Takeovers and Mergers.

Details of any restrictions on the transfer of securities

There are no restrictions on the transfer of securities.

Presentations, circulars, Proxy Forms and Admission Document 

Please click on the link below to access the Company’s current presentation
IMM Corporate Presentation (April 2020)

Please click here for the link to access the Company’s Notice of the 2021 Annual General Meeting
IMM Notice of the 2021 Annual General Meeting

Please click on the link below to access the Company’s Proxy Form
IMM Proxy Form: Annual General Meeting to be held on Monday 28 June 2021

Please click on the link below to access the Company’s circulars
IMM Circular February 2016 Fundrasing

Please click on the link below to access the Company’s Proxy Forms
IMM Proxy Form February 2016 Fundraising

Please click on the link below to access the Company’s Admission Document (January 2006).
ImmuPharma Admission Document

Please click on the link below to access the Company’s ‘Information Note’ as required by the Euronext Growth Market Rules Book and Belgian financial regulations (17 November 2019)
Information Note

Special rules apply when US persons (as defined in the United States securities laws) access this website. For US regulatory reasons, US residents and other US persons who reside outside the United States are not permitted to access this website.  The company is not offering any securities or services in the United States or to residents of the United States through this website or otherwise.  Please refer to our Disclaimer.

Last Updated: 24/08/2021